| ATPIII | IDF | Harmonized | Who | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Group | No MS | MS | Diff (95% CI) | No MS | MS | Diff (95% CI) | No MS | MS | Diff (95% CI) | No MS | MS | Diff (95% CI) |
Age ≥ 65 | 12 | 19 | 7 (3-11)‡ | 15 | 18 | 3 (-2-7) | 11 | 18 | 7 (2-12)†| 8 | 19 | 11 (8-14)‡ |
Age < 65 | 11 | 12 | 0 (-3-3) | 13 | 11 | -2 (-5-2) | 11 | 12 | 0 (-3-4) | 7 | 12 | 5 (3-8) ‡ |
Male | 12 | 18 | 6 (3-9)‡ | 16 | 17 | 1 (-2-5) | 12 | 17 | 5 (2-9)†| 9 | 18 | 9 (6-12) ‡ |
Female | 9 | 10 | 1 (-4-5) | 7 | 10 | 2 (-2-7) | 7 | 10 | 2 (-3-8) | 5 | 11 | 5 (2-8) ‡ |
Prior CVD | 22 | 26 | 3 (-4-10) | 26 | 25 | -1 (-9-6) | 19 | 26 | 7 (-2-16) | 18 | 26 | 8 (0-15)* |
No prior CVD | 9 | 11 | 2 (-0-5) | 11 | 11 | -0 (-3-3) | 10 | 11 | 1 (-2-4) | 6 | 12 | 6 (4-8) ‡ |
All patients | 11 | 14 | 3 (1-5)* | 14 | 14 | -0 (-3-3) | 11 | 14 | 3 (0-6)* | 8 | 15 | 8 (5-10) ‡ |